CareLit · DOI-Nachweis · Pneumologie
Effect of aclidinium bromide/formoterol fumarate fixed-dose combination on exacerbations in moderate-to-severe COPD: Pooled analysis of two studies
DOI 10.1055/s-0035-1544792
Bibliografische Angaben
Nachweis in CareLit
Autor:innenED Bateman, S Rennard, PW Jones, E Molins, V Mergel, A Leselbaum
ZeitschriftPneumologie
Ausgabe02/2015
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background: Aclidinium/formoterol 400/12 µg fixed-dose combination (FDC) is in development for the treatment of COPD. We present pooled COPD exacerbation data from two Phase III studies. Methods: ACLIFORM and AUGMENT were 24-week, randomized, double-blind Phase III studies of aclidinium/formoterol FDC in patients with moderate-to-severe COPD. Treatment arms were FDC 400/6 µg, FDC 400/12 µg, aclidinium 400 µg, formot…
Zitieren
Zitierempfehlung
ED Bateman, S Rennard, PW Jones, E Molins, V Mergel, A Leselbaum (2015) Effect of aclidinium bromide/formoterol fumarate fixed-dose combination on exacerbations in moderate-to-severe COPD: Pooled analysis of two studies. Pneumologie (02). https://doi.org/10.1055/s-0035-1544792
Mit CareLit weiterarbeiten